Zoltan Labs Consulting

Major Effects of Low Doses of ZKCPr1 on Excess Visceral and Metabolic Disorders

The Effects of ZKCPr1, Recombinant or Highly Purified, Applied Subcutaneously or Intravenously Once per Week are Similarly Achieved with 0.04-0.1 mg/Mouse Doses
The Effects of ZKCPr1 Applied Orally at a Dose of 0.1 mg/Mouse every 5th Day were Similar to Those Achieved by Systemic Applications
In Obese Diabetic Mice, the Above Doses of ZKCPr1 Reduced Excess Visceral Fat by 80-90% by either Application Method with Changing Body Weight by less than 15%
In Obese Diabetic Mice, the Above Doses of ZKCPr1 Reduced Elevated Blood Glucose by 60-70%, Increased Serum Insulin by ~90%, and Elevated Blood Levels of Triglycerides and LDL-Cholesterol by ~90% and 50-60%, Respectively
In Obese Diabetic Mice, the Above Doses of ZKCPr1 Reversed the Loss of Muscle Proteins
In a Non-Obese Young Mouse Model ZKCPr1 Almost Completely Reduced Excess Visceral, Experimentally Developed by Limited Exposure to High Fat Diet
In a Non-Obese Old Mouse Model Subcutaneous ZKCPr1 Almost Completely Reduced Excess Visceral, Experimentally Developed by Limited Exposure to High Fat Diet, Resulting in ~25% Increase in Survival
In Already Modestly Obese Diabetic Mice Weekly Subcutaneous Administration of 0.3 mg/mouse ZKCPr1 Reduced Further Weight Gain Along with Near Normalization of Visceral Fat